{"id":49998,"date":"2022-10-24T19:02:10","date_gmt":"2022-10-24T17:02:10","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\/"},"modified":"2022-10-24T19:02:10","modified_gmt":"2022-10-24T17:02:10","slug":"clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\/","title":{"rendered":"ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022"},"content":{"rendered":"
\n

CONCORD, Mass.–(BUSINESS WIRE)–ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure in patients chronically infected with Hepatitis B, announced today that two abstracts were accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting, to be held in Washington, DC, USA, November 4 \u2013 8, 2022.\n<\/p>\n

\n\u201cWe are excited to continue to make the Hepatitis B community aware of our progress for the therapeutic vaccine candidate CLB-3000, toward first in human trials and our confidence in this novel and differentiated approach\u201d said Aileen Rubio, PhD., CEO for the company. Chronic infection with Hepatitis B (CHB) remains a significant global disease infecting hundreds of millions of people, where functional cure remains elusive and combination therapies are likely needed. We believe that re-education of patients\u2019 immune systems to break tolerance of their chronic HBV infections through administration of ClearB\u2019s therapeutic vaccine could become an important component of combination treatment regimens.\u201d\n<\/p>\n

\nAbstract Number \/ Poster Number:<\/b> 36528 \/ SAT1193
\n
Abstract Title<\/b> : Evaluation of the Hepatitis B therapeutic vaccine candidate CLB-3000 (CLB-405 + CLB-505 with Alhydrogel): a 9- or 15-week toxicity study in New Zealand White (NZW) rabbits with a 4-week recovery period
\n
Date<\/b>: Friday, 4 November 2022
\n
Time<\/b>: 12:00 pm EDT
\n
Presenter Name:<\/b> Aileen Rubio, ClearB Therapeutics\n<\/p>\n

\nAbstract Number \/ Poster Number:<\/b> 37190 \/ SAT1215
\n
Abstract Title<\/b> : Immunogenicity following intramuscular vaccination with increasing dose levels of recombinant Hepatitis B surface antigen (HBsAg) variants CLB-405 and CLB-505 with or without Alhydrogel in New Zealand White (NZW) rabbits
\n
Date<\/b>: Friday, 4 November 2022
\n
Time<\/b>: 12:00 pm EDT
\n
Presenter Name:<\/b> Aileen Rubio, ClearB Therapeutics\n<\/p>\n

\nFor more information regarding AASLD 2022 please visit
\n
The Liver Meeting | AASLD<\/a>\n<\/p>\n

\nAbout ClearB Therapeutics
\n
<\/b>ClearB Therapeutics was co-founded in 2017 by Morningside Ventures in collaboration with Professor Stephen Locarnini and the Victoria Infectious Diseases Reference Laboratory in Melbourne, Australia. ClearB is working to develop therapeutic vaccines designed to drive functional cure of Hepatitis B. The work is grounded in proprietary insights derived from studying rare-event infection resolution in patients who suffer from chronic Hepatitis B. For more information, please visit https:\/\/clearbtherapeutics.com\/<\/a>.\n<\/p>\n

\nAbout Morningside Ventures:<\/b> Morningside was founded in 1986 by the Chan family, to make private equity and venture capital investments in North America, Europe, and Asia Pacific. In the life sciences, Morningside specializes in early-stage (pre-clinical through human proof-of-concept) investments in biopharmaceutical products. They partner with academic founders and entrepreneurs to build world-class companies that want to markedly improve the current state of medicine today and ultimately, the lives of patients. Morningside’s focus is to invest in excellent biomedical research, where a significant body of knowledge has been gathered and there is a plausible path forward in clinical development. Their mission is to contribute to making a meaningful, positive impact on the prevention or treatment of human disease, and believe that so long as this is achieved, commercial success will follow.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nJennifer Locke, Chief Operating & Business Officer
\n
ClearB Therapeutics, Inc.
\n
pr@clearbtherapeutics.com<\/a>
978.202.4335\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CONCORD, Mass.–(BUSINESS WIRE)–ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure in patients chronically infected with Hepatitis B, announced today that two abstracts were accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting, to be held in Washington, DC, USA, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49998","6":"format-standard","7":"category-industry"},"yoast_head":"\nClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CONCORD, Mass.–(BUSINESS WIRE)–ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure in patients chronically infected with Hepatitis B, announced today that two abstracts were accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting, to be held in Washington, DC, USA, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-24T17:02:10+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022\",\"datePublished\":\"2022-10-24T17:02:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\\\/\"},\"wordCount\":499,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\\\/\",\"name\":\"ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-10-24T17:02:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\/","og_locale":"en_US","og_type":"article","og_title":"ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022 - Pharma Trend","og_description":"CONCORD, Mass.–(BUSINESS WIRE)–ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure in patients chronically infected with Hepatitis B, announced today that two abstracts were accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting, to be held in Washington, DC, USA, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-24T17:02:10+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022","datePublished":"2022-10-24T17:02:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\/"},"wordCount":499,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\/","url":"https:\/\/pharma-trend.com\/en\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\/","name":"ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-10-24T17:02:10+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/clearb-therapeutics-announces-upcoming-poster-presentations-of-pre-clinical-hepatitis-b-data-at-aasld-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49998"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49998\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49998"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49998"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}